The Rheumatology Drugs for COVID-19 Management : Which and When?

INTRODUCTION: While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, and tumor necrosis factor (TNF)-α, which hallmarks the most severe clinical cases. 'Repurposing' immunomodulatory drugs and applying clinical management approved for rheumatic diseases represents a game-changer option. In this article, we will review the drugs that have indication in patients with COVID-19, including corticosteroids, antimalarials, anti-TNF, anti-IL-1, anti-IL-6, baricitinib, intravenous immunoglobulins, and colchicine. The PubMed, Medline, and Cochrane Library databases were searched for English-language papers concerning COVID-19 treatment published between January 2020 and October 2020. Results were summarized as a narrative review due to large heterogeneity among studies. In the absence of specific treatments, the use of immunomodulatory drugs could be advisable in severe COVID-19 patients, but clinical outcomes are still suboptimal. An early detection and treatment of the complications combined with a multidisciplinary approach could allow a better recovery of these patients.

Media Type:

Electronic Article

Year of Publication:

2021

Contained In:

Journal of clinical medicine - Vol. 10, No. 4 (2021)

Language:

English

Contributors:

Atzeni, Fabiola
Masala, Ignazio Francesco
Rodríguez-Carrio, Javier
Ríos-Garcés, Roberto
Gerratana, Elisabetta
La Corte, Laura
Giallanza, Manuela
Nucera, Valeria
Riva, Agostino
Espinosa, Gerard
Cervera, Ricard

Urls:

Volltext

Keywords:

Anti-IL-6 drugs
COVID-19
HCQ
Journal Article
Pneumonia
Review
SARS-CoV2

Notes:

Date Revised 09.03.2021

published: Electronic

Citation Status PubMed-not-MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.3390/jcm10040783

PMID:

33669218

PPN (Catalogue-ID):

NLM32334125X